Physician profile
Marcus R Stonecipher
NPI 1801904354
$2,294.78
in general payments reported to CMS, 2019-2025
19 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,320 · 2020: $107 · 2021: $205 · 2022: $198 · 2023: $259 · 2024: $84.28 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,132.17 | 2019-2021 | |
| Abbvie INC. | $285.93 | 2019-2023 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $116.94 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $101.34 | 2019-2022 | |
| Genzyme Corporation | $72.44 | 2019-2023 | |
| Lilly USA, LLC | $68.85 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $67.54 | 2019-2023 | |
| Arcutis Biotherapeutics, INC. | $65.70 | 2023-2025 | Zoryve |
| Pfizer INC. | $57.83 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.89 | 2020-2025 | Siliq, Jublia, Cabtreo |
| Incyte Corporation | $45.83 | 2021-2022 | |
| Leo Pharma INC. | $40.52 | 2022-2024 | Adbry |
| Ucb, INC. | $39.23 | 2023 | Cimzia |
| Amgen INC. | $36.04 | 2020-2023 | Otezla, Enbrel |
| Sun Pharmaceutical Industries INC. | $34.35 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strata Skin Sciences, INC. | $29.94 | 2021-2024 | Xtrac |
| Organon LLC | $22.32 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.19 | 2024 | Spevigo |
| Galderma Laboratories, L.P. | $12.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Stonecipher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.